País: Malta
Idioma: inglés
Fuente: Medicines Authority
atovaquone 250 mg, proguanil hydrochloride 100 mg
1 A Pharma GmbH
P01BB51
atovaquone, proguanil hydrochloride
film-coated tablet
Authorised
2013-06-25
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER REPRAPOG 250 MG/100 MG FILM-COATED TABLETS atovaquone/proguanil hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE, BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. − If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Reprapog is and what it is used for 2. What you need to know before you take Reprapog 3. How to take Reprapog 4. Possible side effects 5. How to store Reprapog 6. Contents of the pack and other information 1. WHAT REPRAPOG IS AND WHAT IT IS USED FOR Reprapog belongs to a group of medicines called antimalarials. It contains two active ingredients, atovaquone and proguanil hydrochloride. Reprapog has two uses: • to prevent malaria in adults and children who weigh at least 40 kg • to treat malaria in adults and children who weigh at least 11 kg Malaria is spread by the bite of an infected mosquito, which passes the malaria parasite (Plasmodium falciparum) into the bloodstream. Reprapog prevents malaria by killing this parasite. For people who are already infected with malaria, Reprapog also kills these parasites. _Protect yourself from catching malaria _ People of any age can get malaria. It is a serious disease, but is preventable. As well as taking Reprapog, it is very important that Leer el documento completo
Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Reprapog 250 mg/100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: 250 mg atovaquone and 100 mg proguanil hydrochloride For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Pink, round, biconvex film coated tablets debossed with 'H' on one side and '175' on the other side. Thickness of the tablet is 11.10 mm (± 0.20) and diameter 5.40 mm (± 0.30). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of _Plasmodium falciparum_ malaria in adults and in children weighing at least 40 kg. Treatment of acute, uncomplicated _Plasmodium falciparum_ malaria in adults and in children weighing at least 11 kg. Official guidelines and local information on the prevalence of resistance to antimalarial drugs should be taken into consideration. Official guidelines will normally include WHO and public health authorities‘ guidelines. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology PROPHYLAXIS Prophylaxis should • commence 24 or 48 hours prior to entering a malaria-endemic area • continue during the period of the stay • continue for 7 days after leaving the area. In residents (semi-immune subjects) of endemic areas, the safety and effectiveness of atovaquone/proguanil has been established in studies of up to 12 weeks. In non-immune subjects, the average duration of exposure in clinical studies was 27 days. _Adults and children weighing at least 40 kg _ One Reprapog tablet daily. Page 2 of 11 Reprapog tablets are not recommended for malaria prophylaxis in persons under 40 kg bodyweight. TREATMENT Dosage in Adults Four Reprapog Leer el documento completo